CvergenX Acquires Global Rights Of InterveneXRT

CvergenX, Inc. and Moffitt Cancer Center announced that they have signed a licensing agreement, which includes CvergenX having the exclusive global rights of InterveneXRT. The latter is a technology platform that provides individualization of radiotherapy. InterveneXRT was developed by researchers from Moffitt Cancer Center.


http://www.healthimaginghub.com/article/1655-cvergenx-acquires-global-rights-of-intervenexrt.html